Tirzepatide 5 mg vial (GLP1+GIP)

Tirzepatide 5mg - structural characteristics

Tirzepatide 5mg is a synthetic peptide analog designed as a dual agonist of GIPR and GLP-1R receptors. The molecule consists of an amino acid sequence optimized for enzymatic stability and extended half-life. The structural modifications used, including amino acid substitutions and coupling to the lipid chain, allow reversible binding to albumin, which reduces renal clearance and increases stability in the biological environment.

Spectrometric and chromatographic (HPLC/UPLC) analyses used for quality control confirm the high purity of the substance used in the study.

Mechanism of receptor action - Tirzepatide 5mg

Tirzepatide at a dose of 5 mg shows agonist activity against two key incretin receptors belonging to the GPCR family - GIPR and GLP-1R - in research models. Dual activation of these pathways leads to an integrated metabolic response, including both regulation of glucose metabolism and modulation of energy balance.

At the cellular level, it is observed:

• An increase in intracellular cAMP concentration,
• Increased glucose-dependent insulin secretion,
• Regulation of glucagon secretion under hyperglycemic conditions,
• Slowing down gastric emptying,
• Effects on central satiety mechanisms within the hypothalamus.

In clinical studies, activation of the GIP/GLP-1 axis has been shown to be associated with changes in body weight parameters, including fat reduction and improved metabolic indices. This mechanism is interpreted as a synergistic effect resulting from the simultaneous modulation of several key hormonal pathways responsible for regulating appetite, energy intake and substrate metabolism.

The 5-mg dose was one of the benchmarks in the dose-effect analyses, allowing assessment of the pharmacodynamic profile and tolerability under controlled study conditions.

Effects on metabolic parameters in studies

In the study SURMOUNT-1 published in New England Journal of Medicine (2022) reported an average weight reduction of about 15% at the 5 mg dose after 72 weeks of follow-up. Changes in waist circumference, lipidogram and markers of insulin resistance were also included in the analyses.

The SURPASS program evaluated the effect of tirzepatydu on HbA1c in patients with type 2 diabetes, showing a statistically significant reduction relative to comparative therapies.

Thirzepatide 5mg as a laboratory reagent

In the research community, formulations based on the tirzepatydu molecule are used as:

• reference material for incretin receptor studies,
• GPCR signaling analysis tool,
• Pharmacological model in energy homeostasis regulation projects.

The substance is intended for research and analytical use only (Research Use Only).

Online availability and where to buy Tirzepatide 5 mg

Reference materials defined as tirzepatide 5 mg can be offered by specialized chemical reagent suppliers. Verification should include quality documentation (CoA, HPLC profile), storage conditions and RUO determination. Does not constitute a product for clinical use outside of approved studies.

Source:

Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.